Anteris Technologies Ltd. announced the presentation of "DurAVR transcatheter aortic valve first-in- human study: impact of novel leaflet design" at the annual PCR London Valves 2022, 27-29 November 2022. Anteris was honoured to accept an opportunity from the PCR Conference Scientific Committee to present at the TAVI: Late-Breaking Trials and Innovations session. The conference was attended by more than 3,000 participants from over 100 countries.

Dr Chris Meduri, MD, Anteris Chief Medical Officer and Interventional Cardiologist, Karolinska University Hospital, Stockholm, presented results from the DurAVR transcatheter aortic valve first-in-human study, providing preliminary echo, CT, and MRI evidence of improved haemodynamic and laminar flow characteristics associated with the DurAVR Transcatheter Heart Valve (THV) System. This prospective, non-randomised, single-arm, single-centre study to evaluate the safety and feasibility of DurAVR THV was conducted in a patient cohort of 13 subjects with severe symptomatic aortic stenosis including challenging anatomies such as Type 1 bicuspid and extreme leaflet calcium. Post-procedural outcomes from the study demonstrated: Mean annulus diameter 22.3 ± 1.07 mm; Mean valve leaflet coaptation length of 8.3 mm; 100% procedural success; No device-related complications; No moderate or severe paravalvular leak; Excellent haemodynamic results at 30 days; Consistent laminar aortic flow shown at 30 days echo and CT results; Improved exercise capacity as measured by 6MWT (first 5 subjects only); No changes in cardiac electrical conductivity at 6 months (first 5 subjects only).